



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/938,754	08/24/2001		Samuel J. Danishefsky	2003080-0083 (SK-943-US)	4106
24280 7	590	04/18/2003			
Choate, Hall				EXAMI	NER .
Exchange Place 53 State Street				COLEMAN, BRENDA LIBBY	
Boston, MA 02109			ſ	ART UNIT	PAPER NUMBER
				1624	11/
				DATE MAILED: 04/18/2003	14

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
•		09/938,754	DANISHEFSKY ET AL.					
	Office Action Summary	Examin r	Art Unit					
		Brenda L. Coleman	1624					
	The MAILING DATE of this communication appears on the cover she to with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1)🖂	Responsive to communication(s) filed on 05 F	ebruary 2003 .						
2a) <u></u> □	This action is FINAL . 2b)⊠ Thi	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims	•						
4)⊠	Claim(s) $\underline{1-56}$ is/are pending in the application							
	4a) Of the above claim(s) 5,6,23 and 29 is/are withdrawn from consideration.							
5) 🗌	Claim(s) is/are allowed.							
6)	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
-	Claim(s) <u>1-4,7-22,24-28 and 30-56</u> are subject	to restriction and/or election requ	uirement.					
Applicati	on Papers							
9)☐ The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
	Applicant may not request that any objection to the	-· ·	, ,					
11)[The proposed drawing correction filed on		ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.								
12)☐ The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
· .	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)[☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents							
	2. Certified copies of the priority documents	have been received in Application	on No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14)⊠ A	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment	(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)					
S. Patent and Tr	adamad Office							

Art Unit: 1624

DETAILED ACTION

Response to Amendment

The applicants' election of Group I is acknowledged. However, upon further review of the record the following additional requirement for restriction is deemed necessary.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, 7-22, 24-28, 30, 33-35 and 38, drawn to the compounds, compositions and method of use of formula I where X is O, classified in class 549, subclasses 268, 269 and 270.
- II. Claims 31, 32, 36 and 37, drawn to complex compositions of formula I where X is O and their method of use, class 514, various subclasses within dependent on the additional therapeutic agents.
- III. Claims 39-46, drawn to the method of use of the compounds of formula I where X is O, classified in class 514, subclasses 434, 436 and 450.
- IV. Claims 47-56, drawn to the process of preparing the compounds of formula I where X is O, classified in class 549, subclasses 268, 269 and 270.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially

Art Unit: 1624

different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the compound known as radicicol is a compound of formula I which is a known to have antitumor effects as shown by Roe et al., Journal of Medicinal Chemistry, 1999, Vol. 42, pages 260-266.

Inventions I and IV are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the compound known as radicicol is a compound of formula I which is prepared using Scheme I of Lampilas et al., Tetrahedron Letters, 1992, Vol. 33, No. 6, pages 777-780.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II-IV, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: include the species of claims 22 and 24-28.

Art Unit: 1624

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, the applicants' elected the species of claim 27.

Applicant is advised that a reply to this requirement must include a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1624

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 703-305-1880. The examiner can normally be reached on 8:30-5:00 Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Brenda Coleman

Primary Examiner Art Unit 1624

April 17, 2003